Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at Needham & Company Following Nuplazid Schizophrenia Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 20.47 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.47 | 52 Week High | $42.49 | |||
| Open | $20.47 | 52 Week Low | $16.64 | |||
| Day High | $20.47 | P/E | N/A | |||
| Day Low | $20.47 | EPS | $-0.42 | |||
| Volume | 14,893 | |||||
